Advertisement

Clinical Studies and New Developments with Hybri-BREScan (CA-549), A Monoclonal Assay for Breast Cancer-Associated Antigen

  • Kurtis R. Bray
  • Isaac A. Mizrahi
  • Marie-Jeanne Yerna

Abstract

Hybri-BREScan antigen (formerly CA-549) is a circulating tumor associated antigen that is often elevated in the sera of breast cancer patients. Preliminary studies of this antigen have shown it to have utility in the monitoring of breast cancer disease status. Biochemical analyses have shown that this antigen is a member of the heterogeneous family of high molecular weight, mucin-like glycoproteins found in human milk fat globule membranes.

Clinical trials at four sites using Hybri-BREScan immuno-radiometric assay to measure antigen in serum showed good assay performance: interassay precision and intra-assay precision were 6.2% and 5.2% cv, respectively, with a minimum detectable concentration of 0.12 U/ml. The normal range was determined to be 0–12 U/ml.

Keywords

Breast Cancer Breast Cancer Patient Radiometric Assay Clinical Trial Site Interassay Precision 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    R. Lamerz, Serial carcinoembryonic antigen (CEA) determinations in the management of metastatic breast cancer. Oncodev Biol Med. 1:123 (1980).PubMedGoogle Scholar
  2. 2.
    D. F. Hayes, M.T. Sekine, M. Abe, K. Keefe, and D.W. Kufe, Use of murine monoclonal antibody for detection of circulating plasma DF3 antigen in breast cancer patients, J Clin Invest. 75:1671 (1985).PubMedCrossRefGoogle Scholar
  3. 3.
    J. Hilkens, V. Kronen, J.M.G. Bonfrer, M. DeJong-Baker and P.F. Bruning, MAM-6 antigen, a new serum marker for breast cancer monitoring, Cancer Res 46:2582 (1986).PubMedGoogle Scholar
  4. 4.
    M. R. Price, G. Crocker, S. Edwards, I.S. Nagra, R.A. Robins, M. Williams, R.W. Blamey, D.M. Swallow, and R.W. Baldwin, Identification of a monoclonal antibody-defined breast carcinoma antigen in body fluids, Eur J Cancer Clin Ono, 23:1169 (1987).CrossRefGoogle Scholar
  5. 5.
    P. S. Linsley, V. Ochs, S. Laska, D. Horn, D.B. Ring, A.E. Frankel, and J.P. Brown, Elevated levels of a high molecular weight antigen detected by antibody W1 in sera from breast cancer patients, Cancer Res, 46:5444 (1986).PubMedGoogle Scholar
  6. 6.
    K. R. Bray, J.E. Koda, and P.K. Gaur, Serum levels and biochemical characteristics of cancer associated antigen CA-549,a circulating breast cancer marker, Cancer Res, 47:5853 (1987).PubMedGoogle Scholar
  7. 7.
    K. R. Bray, and P.K. Gaur, Correlation of serum levels of CA-549 to disease status in post-treatment serial samples from breast cancer patients, J Clin Lab Anal, 2:134 (1988).CrossRefGoogle Scholar
  8. 8.
    R. A. Beveridge, D.W. Chan, D. Bruzek, D. Damron, K.R. Bray, P.K. Gaur, D.S. Ettinger, R.C. Rock, S. Shurbaji, and F.P. Kuhajda, A new biomarker in monitoring breast cancer: CA 549, J Clin Oncol, 6:1815 (1988).PubMedGoogle Scholar
  9. 9.
    D. K. Werneke, R.L. Elliot, and K.R. Bray, The comparative incidence of elevation of tumor markers CA-549, CA-15.3, and CEA in the sera of breast cancer patients, Clin Chem, 35:1078 (1989).Google Scholar

Copyright information

© Springer Science+Business Media New York 1991

Authors and Affiliations

  • Kurtis R. Bray
    • 1
    • 2
  • Isaac A. Mizrahi
    • 1
    • 2
  • Marie-Jeanne Yerna
    • 1
    • 2
  1. 1.Hybritech IncorporatedSan DiegoUSA
  2. 2.Hybritech IncorporatedLiegeBelgium

Personalised recommendations